Monocentric phase 1 dose-escalation study of siltuximab in combination with idarubicin and cytarabine chemotherapy in patients with poor prognosis acute myelogenous leukemia (AML): SILTUXILAM

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501171-14-00

Acronym

RC22_0233

Enrollment

Registered

2022-11-28

Start date

2023-03-13

Completion date

Unknown

Last updated

2025-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adult patients with acute myeloblastic leukemia (AML) of poor prognosis first Line or Relapse

None listed

Sex/Gender

All

Age

18 Years to No maximum

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026